Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-519 and Rosuvastatin Interaction Study
NCT03175835Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocacetrapib in dyslipidemia, sponsored by Chong Kun Dang Holdings. Primary endpoint: Area under the plasma concentration versus time curve (AUCtau) at Day 26. Started May 2017; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03175835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175835.